

Technology Advisory Committee A Interests Register

Pembrolizumab with chemotherapy for treating HER2-negative advanced gastric or gastro-oesophageal junction adenocarcinoma [ID4030]

Publication Date: TBC

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Prithwiraj Das	Committee C Member	Indirect - Financial Interests	Prithwiraj works in life sciences, including pharmaceutical market access, as Founding Director of G2PR ltd. I have not worked on these products/indications in the last 12+ months.	05/02/2024	It was agreed that Prithwiraj's declaration would not prevent him from being part of the committee.
Dr Patrick De Barr	Committee A Member	Direct – financial interests	Patrick received paid employment from a company who have a PD1 antibody under development, however this is in a different indication.	25/01/2024	It was agreed that Patrick's declaration would not prevent him from being part of the committee.

DRAFT